Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on January 8, 2018. The registrant is a Delaware corporation and has elected to be treated as an emerging growth company. The report details an amendment to the employment agreement of a senior executive.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to executive compensation:
- Executive Base Salary: $343,000 annually (Thomas Wessel, M.D., Ph.D., Chief Medical Officer).
- Target Bonus: 45% of base salary.
- Time Commitment: 80% of business time devoted to the Company.
Material Changes
The material change reported is the amendment to the offer letter for Dr. Thomas Wessel, effective January 8, 2018. This amendment formalizes his compensation structure and time commitment requirements. No other material changes to the company's operations or financial status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. The document is strictly limited to the disclosure of the executive compensation amendment.
Investor Verification Checklist
- Verify the full text of the Amendment to Offer Letter (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that this filing provides no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.